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Safety Issues
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OBJECTIVES The aim of this study was to evaluate the mode of death in patients with advanced chronic
heart failure (HF) and intraventricular conduction delay treated with optimal pharmacologic
therapy (OPT) alone or OPT with biventricular pacing to provide cardiac resynchronization
therapy (CRT) or CRT  an implantable defibrillator (CRT-D).
BACKGROUND Limited data are available on mode of death in advanced HF. No data have existed on mode
of death in these patients who also have an intraventricular conduction delay and are treated
with CRT or CRT-D.
METHODS Using prespecified definitions and source materials, seven cardiologists assessed mode of
death among the 313 deaths that occurred in the Comparison of Medical, Pacing, and
Defibrillation Therapies in Heart Failure (COMPANION) trial.
RESULTS A primary cardiac cause was present in 78% of deaths. Pump failure (44.4%) was the most
common mode of death followed by sudden cardiac death (SCD) (26.5%). Compared with
OPT, CRT-D significantly reduced the number of cardiac deaths (38%, p  0.006), whereas
CRT alone was associated with a non-significant 14.5% reduction (p 0.33). Both CRT and
CRT-D tended to reduce pump failure deaths (29%, p  0.11 and 27%, p  0.14,
respectively). The CRT-D significantly reduced SCD (56%, p  0.02), but CRT alone did
not.
CONCLUSIONS Pump failure deaths are the predominant mode of death in patients with advanced HF and
are modestly reduced by both CRT and CRT-D. Only CRT-D reduced SCD and thus
produced a favorable effect on cardiac mortality. (J Am Coll Cardiol 2005;46:2329–34)
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.09.016© 2005 by the American College of Cardiology Foundation
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whronic heart failure (HF) is characterized by a progressive
ourse of increasing symptoms, recurrent hospitalizations,
nd shortened survival, all likely mediated by ventricular
remodeling”(1). Advances in HF therapy, principally neu-
ohormonal blockade, have reduced the annual mortality in
atients with mild to moderate HF from nearly 16% to 6% to
% (2–9). However, recent trials of further additive pharma-
ologic therapy have been largely disappointing (9–12).
oreover, in advanced HF, annual mortality rates with
From the *Veterans Affairs Medical Center, Washington, DC; †Division of
ardiology, Veterans Affairs Medical Center, Minneapolis, Minnesota; ‡Division of
ardiology, Duke University, Durham, North Carolina; §Advanced Heart Failure
nd Cardiac Transplant Programs, Sharp Memorial Hospital, San Diego, California;
Division of Cardiology, St. Luke’s-Roosevelt Hospital, New York, New York;
Clinical Cardiovascular Research, Gaithersburg, Maryland; #Division of Cardiol-
gy, University of Colorado, Denver, Colorado; **Louisiana State University Medical
enter, Shreveport, Louisiana; ††University of Wisconsin, Madison, Wisconsin; and
‡Jefferson Medical College, Philadelphia, Pennsylvania. This analysis was funded by
grant from the Guidant Corporation, St. Paul, Minnesota.c
Manuscript received March 1, 2005; revised manuscript received August 24, 2005,
ccepted September 8, 2005.uccessful therapies (11.25%—beta blocker in Carvedilol
rospective Randomized Cumulative Survival Study
COPERNICUS] [7], 17.5%—aldosterone antagonist in
andomized Aldactone Evaluation Study [RALES] [8]) sug-
est limitations of currently available medical therapy. To
urther improve prognosis, two electrophysiologic device-
elated therapies have been evaluated in HF: 1) intracardiac
efibrillation therapy (implantable cardioverter-defibrillator
ICD]) targeting ventricular arrhythmias; and 2) cardiac
esynchronization therapy (CRT), targeting ventricular dys-
ynchrony. The Comparison of Medical, Pacing, and De-
brillation Therapies in Heart Failure (COMPANION)
rial (13) tested both CRT and CRT  ICD (CRT-D) in
n advanced HF population with a prolonged QRS. Study
esults showed that time to all-cause mortality was reduced
y 24% with CRT and by 36% with CRT-D when compared
ith optimal pharmacologic therapy (OPT).
Mode of death analysis provides an understanding of thelinical course of the disease in the study population and
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Mode of Death in Advanced Heart Failure December 20, 2005:2329–34ffers insights into mechanism of action of the therapeutic
odality. This analysis was undertaken to examine the
ode of death in a group of patients with advanced HF
rom the COMPANION study in order to better under-
tand the manner of potential benefit from therapy with
RT and CRT-D.
ETHODS
he COMPANION study was a randomized, placebo-
ontrolled trial that tested the hypothesis that CRT and
RT-D would reduce the risk of death and hospitalization
n patients with advanced HF and prolonged intraventric-
lar conduction (14). A total of 1520 patients in New York
eart Association (NYHA) functional class III or IV with
schemic or dilated cardiomyopathy and QRS duration 120
s were randomly assigned in a 1:2:2 ratio to OPT, CRT,
r CRT-D. All post-randomization deaths, with the excep-
ion of post-cardiac transplantation deaths, were counted as
tudy end points and were adjudicated and classified.
All analyses were by intention to treat. Time to cause-
pecific death was plotted using the Kaplan-Meier method,
nd differences between groups were determined by the
og-rank statistic. Cox proportional-hazards regression models
ere used to estimate the hazard ratios (HRs) and 95%
onfidence intervals (CIs). Details regarding data collection
able 1. Mode of Death Overall, and Within Each Treatment G
Cause of Death
OPT
n (%*) [%†] n
umber of patients 308
ardiac 54 (18.8) [75.3] 109 (
SCD 18 (5.8) [23.4] 48 (
Pump failure 34 (11.0) [44.2] 53 (
Ischemic 4 (1.3) [5.2] 2 (
Cardiac procedure 2 (0.6) [2.6] 6 (
Others 0 (0) [0] 0 (
ascular 0 (0) [0] 5 (
on-cardiac 11 (3.6) [14.3] 14 (
nknown 8 (2.6) [10.4] 3 (
otal 77 (25.0) 131 (
% of deaths by randomized patients within each group. †% of deaths within each t
Abbreviations and Acronyms
CI  confidence interval
COMPANION  Comparison of Medical, Pacing, and
Defibrillation Therapies in Heart
Failure trial
CRT  cardiac resynchronization therapy
CRT-D  cardiac resynchronization therapy
with defibrillator
HF  heart failure
HR  hazard ratio
ICD  implantable cardioverter-defibrillator
NYHA  New York Heart Association
OPT  optimal pharmacologic therapy
SCD  sudden cardiac deathCRT  cardiac resynchronization therapy; CRT-D  cardiac resynchronization therapy
eath.nd censoring for the time to event analyses are described
lsewhere (13). All p values are two-sided and nominal.
ortality definitions. CAUSE OF DEATH. The primary
ode of death refers to the event that led to death. Deaths
ere classified as cardiac or non-cardiac, with more specific
ategories assigned as permitted by the circumstances of the
linical event. For the most common specific categories:
udden cardiac death (SCD) was defined as observed or
nobserved but assumed to be instantaneous because of the
linical setting (SCD was further classified as with or
ithout worsening HF); pump failure death was defined as
progressive HF course manifested by symptoms requiring
ncreased medications, including intravenous agents (pump
ailure death was further classified as progressive deteriora-
ion or recurrent hospitalization).
ESULTS
aseline characteristics of the COMPANION trial patients
ave been published previously (13). In brief, the patient group
tudied had a median age of 69 years, 86% were in NYHA
unctional class III and 14% in class IV, with a median ejection
raction of 21%. The median QRS duration was 160 ms, and
0% had left bundle-branch block. All patients were required
y protocol to be on OPT (89% on angiotensin-converting
nzyme inhibitor or angiotensin receptor blocker, 68% on
eta-blockers, 55% on spironolactone).
verall cohort. The adjudicated causes of death for the
ntire cohort are shown in Table 1. Overall, a cardiac cause of
eath was noted in 78% of patients. Pump failure was the most
ommon cause of death (44.4%) followed by SCD (26.5%).
hen the analysis was carried out separately on the non-device
PT group, there were 44.2% pump failure and 23.4% SCDs.
reatment groups. Mode of death for the three treatment
roups is shown in Table 1. Kaplan-Meier curves for cardiac
nd non-cardiac deaths are shown in Figures 1A and 1B.
here were significantly fewer cardiac deaths in the CRT-D
rm as compared with OPT (p  0.006), but there was no
ifference between the CRT and OPT groups. Non-cardiac
eaths did not differ between treatment groups.
%†]
CRT-D
n (%*) [%†]
Overall
n (%*) [%†]
595 1,510
[83.2] 76 (12.8) [72.4] 243 (16.1) [77.6]
36.6] 17 (2.9) [16.2] 83 (5.5) [26.5]
40.5] 52 (8.7) [49.5] 139 (9.1) [44.4]
1.5] 4 (0.7) [3.8] 10 (0.7) [3.2]
4.6] 2 (0.3) [1.9] 10 (0.7) [3.2]
1 (0.2) [1.0] 1 (0.1) [0.3]
3.8] 3 (0.5) [2.8] 8 (0.5) [2.6]
10.7] 21 (3.5) [20.0] 46 (3.0) [14.7]
2.3] 5 (0.8) [4.8] 16 (1.0) [5.1]
105 (17.6) 313 (20.6)
nt group.roup
CRT
(%*) [
617
17.1)
7.8) [
8.6) [
0.3) [
1.0) [
0) [0]
0.8) [
2.3) [
0.5) [
21.2)
reatme
with defibrillator; OPT  optimal pharmacologic therapy; SCD  sudden cardiac
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December 20, 2005:2329–34 Mode of Death in Advanced Heart FailureAs in the overall cohort, the two most common modes of
ardiac deaths were pump failure and SCD. Other causes such
s ischemia were infrequent (Table 1). Kaplan-Meier curves for
ump failure and SCDs are shown in Figures 2 and 3. As
ompared with OPT, there was a non-significant reduction of
ump failure deaths in both the CRT (HR 0.71, 95% CI 0.46
o 1.09, p  0.11) and CRT-D (HR 0.73, 95% CI 0.47 to
.11, p 0.15) groups. For CRT grouped together (CRT and
RT-D), pump failure deaths were decreased by 29% (HR
.71, 95% CI 0.48 to 1.05, p  0.08). For SCD, there was a
ignificant, 56% reduction in deaths in the CRT-D arm as
igure 1. (A) Kaplan-Meier estimates of the time to first cardiac death. (B
esynchronization therapy; CRT-D  cardiac resynchronization therapy wompared with OPT (HR 0.44, 95% CI 0.23 to 0.86, p  T.02), whereas no reduction was seen with CRT as compared
ith OPT (HR 1.21, 95% CI 0.7 to 2.07, p  0.50).
ISCUSSION
he data from the COMPANION trial provide an oppor-
unity to examine the mode of death in an advanced HF
opulation as well as the effect of device therapies.
ode of death analysis. Mode of death analysis has been
ndertaken in major HF trials and most, like the COM-
ANION trial, have used a committee to adjudicate events.
lan-Meier estimates of the time to first non-cardiac death. CRT  cardiac
efibrillation; OPT  optimal pharmacologic therapy.) Kaphe results, shown in Table 2, demonstrate that the
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Mode of Death in Advanced Heart Failure December 20, 2005:2329–34ajority of deaths were of cardiovascular cause, predomi-
antly sudden and pump failure events. The relative pro-
ortion of these events differs according to the severity of
F and is relevant as they represent different therapeutic
argets. In mild-moderate HF, particularly with
ngiotensin-converting enzyme inhibitor and beta-blocker
herapy, sudden deaths are the most common cause of death
nd pump failure deaths are less frequent (Metropolol
R/XL randomized intervention trial in congestive heart
ailure [MERIT-HF] 1.5%/year; Candesartan in Heart
ailure Assessment of Reduction in Mortality and Morbidity
Figure 2. Kaplan-Meier estimate of the time to first pump failure death. CFigure 3. Kaplan-Meier estimate of the time to first suCHARM] Added program 2.0%/year) (6,15). The impli-
ations are significant for clinical trials in that interventions
hat decrease sudden deaths without any influence on pump
ailure can reduce total mortality, as in the Sudden Cardiac
eath in Heart Failure Trial (SCD-HeFT) (15). Con-
ersely, in the Valsartan Heart Failure Trial (Val-HeFT)
53% sudden deaths), valsartan did not decrease sudden
eaths and therefore did not influence overall mortality (9).
n more advanced HF, where pump failure deaths are more
requent, the therapeutic target is more complex and inter-
entions need to additionally reduce pump failure deaths to
onfidence interval; HR  hazard ratio; other abbreviations as in Figure 1.dden cardiac death. Abbreviation as in Figure 1.
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December 20, 2005:2329–34 Mode of Death in Advanced Heart Failuree successful therapies. In SCD-HeFT the subgroup anal-
sis of NYHA functional class III patients did not show
verall mortality benefit (16). The CARE-HF (17) results
re also illustrative—pump failure deaths comprised the
ajority of events, and while CRT patients experienced
ewer sudden and pump failure deaths, the largest reduction
42%) was in the latter events.
The patient group in the COMPANION trial was a
articularly high-risk HF cohort with a wide QRS interval
ut also a previous HF hospitalization within 12 months.
he predominance of pump failure deaths represented an
mportant therapeutic target, and therefore a device that
ould target both progressive HF and arrhythmic deaths
ould have the greatest likelihood of success as noted in the overall
OMPANION trial results.
Two other points are worth noting on mode of death. 1)
on-cardiac deaths were not altered by therapy within the
verall trial despite a 36% reduction in overall mortality in
RT-D. Such findings raise the question of whether non-
ardiac or non-cardiovascular deaths should be included in
rials testing cardiovascular interventions, because these
vents would provide background noise in an all-cause
ortality analysis and dilute a treatment effect on cardio-
ascular events. Similar findings on noncardiovascular
eaths led the CHARM authors to recently suggest that
ardiovascular deaths might be a more appropriate end
oint for trials testing cardiovascular interventions. 2) Myo-
ardial infarctions are an infrequent adjudicated cause of
eath in HF. Whether these events are undercounted
ecause patients expire before evaluation is uncertain. An
nalysis by Uretsky (18) suggested an underdiagnosis of
yocardial infarction using autopsy data from the Assess-
able 2. Mode of Death in Selected Heart Failure Trials
Trials
Total
Study
N
Total
Mortality
n (%)
Annual
Mortality Rate
(%)
C
ONSENSUS-1 253 118 (46.6) 33 (6 mos) 1
OLVD-T 2,569 962 (37.4) 11.6 8
-HeFT 642 283 (44.1) 16 2
-HeFT 11 804 285 (35.4) 11 2
HF-STAT 674 274 (40.7) 14.9 2
IG study 6,800 2,375 (34.9) 11.3 2,0
RAISE 1,153 413 (35.8) 30.8 3
ERIT-HF 3,991 362 (9.7) 10 3
ERIT-HF-BB 1,990 145 (7.2) 7.3 1
alHeFT 5,010 979 (19.5) 9.5
HARM-Alt 2,028 561 (27.6) 7.5 4
HARM-Add 2,548 789 7.5 6
ARE-HF 813 202 (24.8) 12.6 1
EST 2,708 860 16.6 7
EST 3,833 802 24.1 7
ALES 1,663 670 (40.2) 23 5
% of deaths by all deaths in each trial; †% of deaths by randomized patients in each
BEST  Beta-Blocker Evaluation Survival Trial; CARE-HF  CArdiac REsync
f Reduction in Mortality and morbidity-Added; CHARM-Alt  Candesartan in He
Amiodarone in Patients with Congestive Heart failure and Asymptomatic Ventricu
eart failure; DIG  Digoxin Investigation Group; MERIT-HF  Metropolol C
etropolol CR/XL Randomized Intervention Trial in Congestive Heart Failure-Beta
n Mortality and Morbidity in Patients with Severe Heart Failure; RALES  Random
alHeFT  Valsartan Heart Failure Trial; VEST  Vesnarinone Evaluation of Suent of Treatment with Lisinopril and Survival (ATLAS) trial where evidence of acute ischemic events was more
ommonly seen in deaths classified as sudden than clinical
ata indicated. Future device trials may provide data on the
xtent to which myocardial infarctions are present in pa-
ients in whom ICD therapy prevented SCD.
RT and CRT-D effect. Although either CRT device had
beneficial effect on the progression of HF including a 29%
ecrease in pump failure deaths, the principal mortality benefit
f the COMPANION trial was seen in reduction of SCD
hen CRT was combined with a defibrillator. The SCD
eduction supports previous findings of the Multicenter Auto-
atic Defibrillator Implantation Trial II (MADIT-II) (19)
post-myocardial infarction ischemic cardiomyopathy), and the
ore recent SCD-HeFT (16). Sudden cardiac deaths were
ot decreased in the CRT group, and while the point
stimate appears unfavorable, wide confidence intervals
ake interpretation uncertain. Further, other available data
o not support an increased risk for SCD with the use of
RT. Electrical dispersion has been noted in some left
entricular pacing animal models, but biventricular pacing
oes not produce this effect (20). Chronic controlled human
tudies with CRT therapy do not demonstrate an increased
isk of ICD shocks compared with controls (21). Finally, in
he CARE-HF study (17), CRT reduced SCD although
he larger reduction was in pump failure deaths.
It is of interest to note that the SCD curves separate later
han the pump failure curves in the COMPANION trial.
he relatively late separation of SCD curves has been noted
n both the MADIT-II (19) and SCD-HeFT (16) trials.
oss et al. (22) addressed this phenomenon in the
ADIT-II trial and, at least in part, ascribed it to an early
reponderance of non-SCD events. This would be a poten-
ovascular
eath
*) [%†]
Sudden Death
n (%*) [%†]
Pump Failure
Death
n (%*) [%†]
Myocardial
Infarction
n (%*)
9.1) [46.2] 39 (33.3) [15.4] 66 (55.9) [26.1] 3 (2.5)
9.4) [33.5] 218 (22.7) [8.5] 460 (47.8) [17.9] 93 (9.7)
4.3) [41.6] 164 (58.0) [25.5] 89 (31.4) [13.9] 14 (4.9)
7.4) [30.9] 149 (52.3) [18.5] 90 (31.6) [11.2] 10 (3.5)
3.6) [33.9] 139 (50.7) [20.6] 74 (27.0) [10.9] No data
5.1) [29.7] 952 (40.1) [14] 843 (35.3) [12.4] No data
9.1) [31.9] 185 (44.8) [16] 165 (40.0) [14.3] 12 (2.9)
1.4) [8.3] 211 (58.3) [5.3] 88 (24.3) [2.2] No data
8.2) [6.4] 79 (54.4) [3.9] 30 (20.8) [1.5] No data
data 520 (53.1) [10.4] 243 (24.8) [4.9] No data
3.9) [23.2] 191 (34) [9.4] 159 (28.3) [28.3] 51 (9.1)
2.3) [25.5] 318 (40.3) [12.5] 208 (26.4) [8.2] 39 (4.9) [1.5]
1) [17.6] 67 (33.1) [8.2] 89 (44.1) [10.9] No data
5) [26.9] 385 (44.8) [14.2] 262 (30.5) [9.7] 23 (2.7)
3.5) [19.6] 410 (51.1) [10.7] 321 (40) [8.4] 19 (2.4)
0.5) [32.5] 192 (28.6) [11.5] 316 (47.1) [19] 32 (4.8)
ation in Heart Failure; CHARM-Add  Candesartan in Heart Failure Assessment
ilure Assessment of Reduction in Mortality and morbidity-Alternative; CHF-STAT
hythmia; CONSENSUS-1 Effects of Enalapril on Mortality in Severe Congestive
Randomized Intervention Trial in congestive Heart Failure; MERIT-HF-BB 
er arm; PRAISE Placebo-Controlled Study to Evaluate the Effects of Amlodipine
Aldactone Evaluation Study; SOLVD-D  Studies of Left Ventricular Dysfunction;
Trial; V-HeFT II  Vasdilator in Heart Failure Trial.ardi
D
n (%
17 (9
60 (8
67 (9
49 (8
29 (8
20 (8
68 (8
31 (9
28 (8
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Mode of Death in Advanced Heart Failure December 20, 2005:2329–34CD were the minority of fatal events. For pump failure
eaths, the earlier curve separation and beneficial trend from
RT in the COMPANION trial is consistent with previ-
us reports of improvement in cardiac size and function
23,24) with the CRT modality, as well as the benefit in
ombined death and HF morbidity previously reported in
he COMPANION trial (13) and now also in CARE-HF
17).
tudy limitations. Because most SCDs were not witnessed,
nformation directly describing the events is limited. However,
he course of these patients and the nature of the events were
arefully considered in choosing this category. When “sudden
ardiac death” was assessed, little or no interval worsening of
F occurred and the death was considered unexpected. In
ome cases where crossover from OPT to device occurred, the
atient withdrew consent for study and for any further follow-
p. Therefore the number of deaths classified as “unknown”
as greater than in other recent trials. Comparisons of time
urves involving modes of death are difficult owing to the
oncept of competing risk and the relative numbers of events.
onclusions. In advanced HF with wide QRS interval,
ump failure is the predominant cause of death. Cardiac
esynchronization therapy modestly reduces this outcome.
he CRT-D device additionally reduces SCD, resulting in
ignificant reductions in cardiac and all-cause mortality.
hese data support the conclusion of the COMPANION
rial that the optimal therapy for patients with advanced HF
nd a wide QRS interval is CRT-D in addition to maxi-
um tolerated medical therapy.
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